Nicolas Poirier
Chief Executive Officer chez OSE IMMUNOTHERAPEUTICS
Fortune : 1 M $ au 31/03/2024
Profil
Nicolas Poirier is currently the Chief Executive Officer & Director at OSE Immunotherapeutics SA since 2022.
Previously, he worked as a Project Manager at Effimune SA. Dr. Poirier has a graduate degree from the University of Nantes and Louis Pasteur University, and an undergraduate degree from the Centre d'Etudes Supérieures de Techniques Industrielles.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 31/12/2022 | 192 802 ( 0,89% ) | 1 M $ | 31/03/2024 |
Postes actifs de Nicolas Poirier
| Sociétés | Poste | Début |
|---|---|---|
| OSE IMMUNOTHERAPEUTICS | Chief Executive Officer | 07/10/2022 |
Anciens postes connus de Nicolas Poirier
| Sociétés | Poste | Fin |
|---|---|---|
Effimune SA
 Effimune SA BiotechnologyHealth Technology Effimune SA engages in the research and development of drugs for transplantation and immune-mediated diseases. It covers the identification of novel therapeutic targets, the development of therapeutics, pilot manufacturing, set-up of animal models, pre-clinical and early clinical development. The company was founded by Maryvonne Hiance, Bernard Vanhove and Sophie Brouard in 2007 and is headquartered in Nantes, France. | Corporate Officer/Principal | - |
Formation de Nicolas Poirier
| University of Nantes | Graduate Degree |
| Centre d'Etudes Supérieures de Techniques Industrielles | Undergraduate Degree |
| Louis Pasteur University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| OSE IMMUNOTHERAPEUTICS | Health Technology |
| Entreprise privées | 1 |
|---|---|
Effimune SA
Effimune SA BiotechnologyHealth Technology Effimune SA engages in the research and development of drugs for transplantation and immune-mediated diseases. It covers the identification of novel therapeutic targets, the development of therapeutics, pilot manufacturing, set-up of animal models, pre-clinical and early clinical development. The company was founded by Maryvonne Hiance, Bernard Vanhove and Sophie Brouard in 2007 and is headquartered in Nantes, France. | Health Technology |
